Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting

Background: In the clinical setting, the economic benefits of direct oral anticoagulants (DOACs) in elderly patients with atrial fibrillation (AF) remain unclear. This study aimed to estimate and compare the cost-effectiveness of DOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) and vitamin K...

Full description

Bibliographic Details
Main Authors: Yue Wu, Chi Zhang, Zhi-Chun Gu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
atrial fibrillation
elderly
direct oral anticoagulants
cost-effectiveness
real-world study
edoxaban
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2021.675200/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2021.675200/full

Similar Items